



Coronavirus Disease 2019 (COVID-19)

Information for Clinicians on Therapeutic Options for Patients with COVID-19

Updated April 7, 2020

There are no drugs or other therapeutics approved by the US Food and Drug Administration to prevent or treat COVID-19. Current clinical management includes infection prevention and control measures and supportive care, including supplemental oxygen and mechanical ventilatory support when indicated. Interim guidelines for the medical management of COVID-19 will be provided soon by the Department of Health and Human Services COVID-19 Treatment Guidelines Panel.

Remdesivir

Remdesivir is an investigational intravenous drug with broad antiviral activity that inhibits viral replication through premature termination of RNA transcription and has in-vitro activity against SARS-CoV-2 and in-vitro and in-vivo activity against related betacoronaviruses. Information about clinical trials of remdesivir is available at [ClinicalTrials.gov](https://clinicaltrials.gov). Remdesivir is also available through an expanded access program from the manufacturer, Gilead Sciences.

Hydroxychloroquine and Chloroquine

Hydroxychloroquine and chloroquine are oral prescription drugs that have been used for treatment of malaria and certain inflammatory conditions. Hydroxychloroquine and chloroquine are under investigation in clinical trials for pre-exposure or post-exposure prophylaxis of SARS-CoV-2 infection, and treatment of patients with mild, moderate, and severe COVID-19. More information on clinical trials can be found at [ClinicalTrials.gov](https://clinicaltrials.gov). FDA issued an [Emergency Use Authorization \(EUA\) to authorize use of chloroquine and hydroxychloroquine](#) from the Strategic National Stockpile for treatment of hospitalized adults and adolescents (weight ≥ 50 kg) with COVID-19 for whom a clinical trial is not available or participation is not feasible.

Other Drugs

Several other drugs (e.g., investigational antivirals, immunotherapeutic, host-directed therapies) are under investigation in clinical trials or are being considered for clinical trials of pre-exposure prophylaxis, post-exposure prophylaxis, or treatment of COVID-19 in the United States and worldwide. Information on registered clinical trials for COVID-19 in the United States is available at [ClinicalTrials.gov](https://clinicaltrials.gov). FDA has issued guidance for administering or studying use of [convalescent plasma for treatment](#) of patients with COVID-19.

Page last reviewed: March 21, 2020